

SUBCUTANEOUS IMMUNE GLOBULINS TABLE

| BRAND NAME | IGIVnex & GAMUNEX® ¹ | Hizentra® ² | Cuvitru ³ | cutaquig® ⁴ |
|---------------------------|--|--|--|--|
| WEBLINK | www.grifols.com | www.cslbehring.ca | www.shirecanada.com | www.octapharma.ca |
| INDICATIONS | Primary Immune Deficiency Secondary Immune Deficiency | Primary Immune Deficiency Secondary Immune Deficiency | Primary Immune Deficiency Secondary Immune Deficiency | Primary Immune Deficiency Secondary Immune Deficiency |
| CONCENTRATION | 10% | 20% | 20% | 16.5% |
| SIZES | 2.5g, 5g, 10g, 20g 20g only for IGIVnex | 1g, 2g, 4g, 10g Prefilled syringes for 1g, 2g | 1g, 2g, 4g, 8g | 1g, 2g, 4g, 8g |
| IgA CONTENT | Not more than 0.084 mg/mL | No more than 50 mg/L | ≤280 mcg/mL with an average concentration of 80 mcg/mL | Not indicated in PM |
| SUGAR CONTENT | Not indicated in Product Monograph | None | None | Not indicated in PM |
| STORAGE TEMPERATURE | +2°C to +8°C | +2°C to +25°C | +2°C to +8°C | +2°C to +8°C |
| RECOMMENDED INFUSION RATE | 20 mL/hr per infusion site | 20 mL/hr per site | 10-20mL/hr per site | 25 mL/hr/site |

Product Monograph (PM) reference : 1.IGIVnex PM July 2017 & GAMUNEX® PM Jan 2016, 2. Hizentra® PM Aug 2019 , 3. Cuvitru PM July 2018, 4. Cutaquig PM Aug 2019

Updated as of **2019-11-19** *CONTENT is subject to change.* This Table is a summary and will not tell you everything about IG products. **DETAILED** information can be found in the **PRODUCT MONOGRAPH** or **PACKAGE INSERT**.